---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-032189"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T21:10:13.203717+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma approves 1-for-35 reverse ADS split effective April 9 to meet Nasdaq bid price rule

## Summary
- ADS ratio changes from 1 ADS = 1 ordinary share to 1 ADS = 35 ordinary shares, effective April 9, 2025.
- Reverse split aims to increase ADS price to comply with Nasdaq's $1.00 minimum bid price requirement.
- Ordinary shares unaffected; new CUSIP for ADS will be 74907L409; ticker QNRX unchanged.
- Holders of DRS and DTC ADSs need no action; certificated holders must surrender every 35 old ADSs for 1 new ADS.
- Company cautions that it cannot guarantee the ratio change will achieve or maintain Nasdaq compliance.

## SEC filing metadata
- accession: 0001104659-25-032189
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925032189/0001104659-25-032189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925032189/tm2511590d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-032189
- JSON: https://secwatch.observer/filing/0001104659-25-032189.json
- Plain text: https://secwatch.observer/filing/0001104659-25-032189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.